Skip to content
lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NervGen Pharma Corp.
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
March 4, 2026
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
February 25, 2026
←
Previous Page
1
2